Jacinta O'Keefe

Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.

Timothy Papaluca, Stuart K Roberts, Simone I Strasser, Katherine A Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J Dore, Amanda J Wade, Jacob George, Simon Hazeldine, James O'Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson, et al.

Journal article  |  2020  |  Clinical Infectious Diseases

BACKGROUND: In clinical trials, HCV salvage treatment with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rat..

Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia

T Papaluca, J O'Keefe, S Bowden, JS Doyle, M Stoove, M Hellard, AJ Thompson

Journal article  |  2019  |  Journal of Clinical Virology

Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake

MH Danchin, J Costa-Pinto, K Attwell, H Willaby, K Wiley, M Hoq, J Leask, KP Perrett, Jacinta O'Keefe, ML Giles, H Marshall

Journal article  |  2018  |  Vaccine

Parental Immunisation Needs and Attitudes Survey in paediatric hospital clinics and community maternal and child health centres in Melbourne, Australia

Jessica C Costa-Pinto, Harold W Willaby, Julie Leask, Monsurul Hoq, Tibor Schuster, Alice Ghazarian, Jacinta O'Keefe, Margie H Danchin

Journal article  |  2018  |  Journal of Paediatrics and Child Health